Key statistics
As of last trade, Aligos Therapeutics Inc (ALGS:NAQ) traded at 9.69, 11.26% above the 52 week low of 8.71 set on Jun 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.60 |
---|---|
High | 10.95 |
Low | 9.50 |
Bid | 9.58 |
Offer | 9.79 |
Previous close | 10.18 |
Average volume | 222.40k |
---|---|
Shares outstanding | 3.20m |
Free float | 2.46m |
P/E (TTM) | -- |
Market cap | 32.54m USD |
EPS (TTM) | -25.99 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 18:33 BST.
More ▼
- Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
- Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aligos Therapeutics Announces Reverse Stock Split
- Aligos Therapeutics Strengthens Board with Two New Independent Directors
- Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
- Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
- Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
- Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
- Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
More ▼